Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630

Article  PubMed  Google Scholar 

Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS et al (2022) Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 386(5):437–448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384(14):1289–1300

Article  CAS  PubMed  Google Scholar 

Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M et al (2023) Lenvatinib plus Pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 24(12):1399–1410

Article  CAS  PubMed  Google Scholar 

Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D et al (2022) Assessing the Safety and Efficacy of two starting doses of Lenvatinib Plus Everolimus in patients with renal cell carcinoma: a randomized phase 2 trial. Eur Urol 82(3):283–292

Article  CAS  PubMed  Google Scholar 

Rendl G, Sipos B, Becherer A, Sorko S, Trummer C, Raderer M et al (2020) Real-World Data for Lenvatinib in Radioiodine-Refractory differentiated thyroid Cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol 2020:8834148

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S et al (2019) Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 118:35–40

Article  CAS  PubMed  Google Scholar 

Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN et al (2018) Lenvatinib for the treatment of Radioiodine-Refractory thyroid Cancer in real-life practice. Thyroid 28(1):72–78

Article  CAS  PubMed  Google Scholar 

Masaki C, Sugino K, Saito N, Akaishi J, Hames KY, Tomoda C et al (2020) Efficacy and limitations of Lenvatinib Therapy for Radioiodine-Refractory differentiated thyroid Cancer: real-world experiences. Thyroid 30(2):214–221

Article  CAS  PubMed  Google Scholar 

Vogelzang NJ, Monnette AM, Wang Y, Wan Y, Xie Y, Robert NJ, Tannir NM (2021) Real-world clinical effectiveness of Lenvatinib/Everolimus in a heavily pretreated Advanced/Metastatic renal cell Carcinoma Population in the US Community Oncology setting. Clin Genitourin Cancer 19(6):531–539

Article  PubMed  Google Scholar 

Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P et al (2024) Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients. Ther Adv Urol 16:17562872241244574

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA et al (2021) Lenvatinib with or without everolimus in patients with metastatic renal cell Carcinoma after Immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies. Oncologist 26(6):476–482

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH (2019) Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. J Pharm Biomed Anal 174:561–566

Article  CAS  PubMed  Google Scholar 

Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 31(5):579–584

Article  CAS  PubMed  Google Scholar 

R Core Team A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2021 [Available from: https://www.r-project.org/

Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z (2016) Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 81(6):1124–1133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hutson TE, Dutcus CE, Ren M, Baig MA, Fishman MN (2016) Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE) and LEN plus EVE in metastatic renal cell carcinoma (mRCC). J Clin Oncol.;34(15)

Powles T, Albiges L, Bex A, Grunwald V, Porta C, Procopio G et al (2021) ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 32(12):1511–1519

Article  CAS  PubMed  Google Scholar 

Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, Dutcus CE et al (2021) Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 147:51–57

Article  CAS  PubMed  Google Scholar 

Tahara M, Takami H, Ito Y, Okamoto T, Sugitani I, Sugino K et al (2024) A prospective cohort study exploring the Effect of Lenvatinib Planned Drug holidays in treatment of differentiated thyroid Cancer. Thyroid 34(5):566–574

Article  CAS  PubMed  Google Scholar 

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J et al (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 69:164–176

Article  CAS  PubMed  Google Scholar